Vistabel Succinct Statement (CH)

Composition: Toxinum botulinicum A from Clostridium botulinum. Powder for solution for injection. Contains human albumin. Appears as thin white deposit that may be difficult to see on the base of the vial. Indication: Temporary improvement when the severity of the following facial lines has an important psychological impact in adult patients: moderate to severe vertical lines between the eyebrows seen at the maximum frown (glabellar lines) and/or moderate to severe lateral canthal lines (crow's feet lines) seen at the maximum smile and/or moderate to severe forehead lines seen at maximum eyebrow elevation. Dosage/Application: Doses of botulinum toxin are not interchangeable from one product to another. Doses recommended in Allergan Units are different from other botulinum toxin preparations. Only to be administered by physicians with appropriate qualifications. Reconstituted solution to be used only for the treatment of one single patient at one session. Not to be injected into a blood vessel. For special treatment dosage recommendations refer to: www.swissmedicinfo.ch. Treatment intervals should not be more frequent than every 3 months. Not recommended in patients < 18 Y. and > 65 Y. Contraindications: Hypersensitivity to the active substance or any of the excipients. Impairment of muscle activity (e.g. M. Gravis). Infection at the proposed injection sites. Warnings/Precautions: prior surgical procedures, injection into vulnerable anatomic structures; immediate notification of the emergency service in the event of swallowing, speech or breathing disorders; Availability of immediate measures for anaphylactic reactions; increased risk of systemic effects in undetected neuromuscular diseases; Too frequent or excessive dosing may enhance the risk of reduced efficacy due to antibody formation; Caution in patients with amyotrophic lateral sclerosis or peripheral neuromuscular disorders. Interactions: The effect of botulinum toxin may be potentiated by aminoglycoside antibiotics, spectinomycin, other medicinal products that interfere with neuromuscular transmission (e.g. neuromuscular blocking agents). Product may not be mixed with other pharmaceutical products. Pregnancy/Lactation: Not recommended. Undesirable Effects: Very common: Headache. Common: Paraesthesia, Eyelid ptosis, brow ptosis, nausea, erythema, skin tightness, localised muscle weakness, face pain, ecchymosis; injection site oedema, injection site pain, injection site irritation, injection site haemorrhage, injection site bruising and haematoma. Packages: 1 vial with 100 Allergan units. Delivery Category: A. Date of Information: January 2020. The complete Information for Professionals can be found under www.swissmedicinfo.ch. MA Holder: Allergan AG, Hardturmstrasse 11, 8005 Zürich.